Some investors asked Changshan Pharmaceutical on an interactive platform. Now that the abenatide supplement information has been submitted, the company will focus on promoting the first clinical phase of avenatide diet pills! On October 12, the company replied that it had submitted data on the indication of abenatide for diabetes and would continue to actively cooperate with the CDE review process. The phase I clinical trial for weight loss indications is being prepared in an orderly manner, and the first test subject has not yet been enrolled. The company has always been steadily advancing relevant clinical trials. New drug development is affected by multiple factors, and there is uncertainty. If significant R&D progress is made in the future, the company will strictly comply with regulatory rules and fulfill its information disclosure obligations in a timely manner.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.